vs
MESA LABORATORIES INC（MLAB）与Ouster, Inc.（OUST）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是Ouster, Inc.的1.0倍（$65.1M vs $62.2M），Ouster, Inc.同比增速更快（106.6% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-37.2M），过去两年Ouster, Inc.的营收复合增速更高（54.8% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Ouster, Inc.是总部位于美国加利福尼亚州旧金山的激光雷达技术企业，主打高分辨率数字化3D激光雷达传感器，产品广泛应用于自动驾驶车辆、工业自动化、机器人、无人机、地图测绘、国防及安防等领域。
MLAB vs OUST — 直观对比
营收规模更大
MLAB
是对方的1.0倍
$62.2M
营收增速更快
OUST
高出103.0%
3.6%
自由现金流更多
MLAB
多$55.2M
$-37.2M
两年增速更快
OUST
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $62.2M |
| 净利润 | $3.6M | — |
| 毛利率 | 64.2% | 60.2% |
| 营业利润率 | 12.2% | 1.5% |
| 净利率 | 5.6% | — |
| 营收同比 | 3.6% | 106.6% |
| 净利润同比 | 316.6% | — |
| 每股收益（稀释后） | $0.65 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABOUST
| Q4 25 | $65.1M | $62.2M | ||
| Q3 25 | $60.7M | $39.5M | ||
| Q2 25 | $59.5M | $35.0M | ||
| Q1 25 | $62.1M | $32.6M | ||
| Q4 24 | $62.8M | $30.1M | ||
| Q3 24 | $57.8M | $28.1M | ||
| Q2 24 | $58.2M | $27.0M | ||
| Q1 24 | $58.9M | $25.9M |
净利润MLABOUST
| Q4 25 | $3.6M | — | ||
| Q3 25 | $2.5M | $-21.7M | ||
| Q2 25 | $4.7M | $-20.6M | ||
| Q1 25 | $-7.1M | $-22.0M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $3.4M | $-25.6M | ||
| Q2 24 | $3.4M | $-23.9M | ||
| Q1 24 | $-254.6M | $-23.8M |
毛利率MLABOUST
| Q4 25 | 64.2% | 60.2% | ||
| Q3 25 | 61.5% | 42.1% | ||
| Q2 25 | 62.0% | 45.2% | ||
| Q1 25 | 61.8% | 41.3% | ||
| Q4 24 | 63.3% | 43.8% | ||
| Q3 24 | 61.3% | 38.3% | ||
| Q2 24 | 64.0% | 33.7% | ||
| Q1 24 | 62.1% | 28.6% |
营业利润率MLABOUST
| Q4 25 | 12.2% | 1.5% | ||
| Q3 25 | 7.8% | -61.4% | ||
| Q2 25 | 5.1% | -76.5% | ||
| Q1 25 | 2.4% | -73.0% | ||
| Q4 24 | 9.2% | -85.1% | ||
| Q3 24 | 6.1% | -98.0% | ||
| Q2 24 | 9.6% | -93.6% | ||
| Q1 24 | -460.6% | -99.5% |
净利率MLABOUST
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.1% | -55.0% | ||
| Q2 25 | 8.0% | -58.8% | ||
| Q1 25 | -11.4% | -67.5% | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | 5.9% | -91.1% | ||
| Q2 24 | 5.8% | -88.4% | ||
| Q1 24 | -432.2% | -91.9% |
每股收益（稀释后）MLABOUST
| Q4 25 | $0.65 | $0.10 | ||
| Q3 25 | $0.45 | $-0.37 | ||
| Q2 25 | $0.85 | $-0.38 | ||
| Q1 25 | $-1.30 | $-0.42 | ||
| Q4 24 | $-0.31 | $-0.46 | ||
| Q3 24 | $0.63 | $-0.54 | ||
| Q2 24 | $0.62 | $-0.53 | ||
| Q1 24 | $-47.26 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $208.6M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $261.7M |
| 总资产 | $434.8M | $349.5M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABOUST
| Q4 25 | $29.0M | $208.6M | ||
| Q3 25 | $20.4M | $244.5M | ||
| Q2 25 | $21.3M | $226.5M | ||
| Q1 25 | $27.3M | $168.2M | ||
| Q4 24 | $27.3M | $172.0M | ||
| Q3 24 | $24.3M | $151.4M | ||
| Q2 24 | $28.5M | $184.2M | ||
| Q1 24 | $28.2M | $187.8M |
总债务MLABOUST
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABOUST
| Q4 25 | $186.7M | $261.7M | ||
| Q3 25 | $178.5M | $247.4M | ||
| Q2 25 | $172.5M | $221.0M | ||
| Q1 25 | $159.8M | $167.9M | ||
| Q4 24 | $155.2M | $180.9M | ||
| Q3 24 | $161.5M | $171.7M | ||
| Q2 24 | $150.7M | $170.6M | ||
| Q1 24 | $145.4M | $167.2M |
总资产MLABOUST
| Q4 25 | $434.8M | $349.5M | ||
| Q3 25 | $430.4M | $353.8M | ||
| Q2 25 | $435.7M | $321.8M | ||
| Q1 25 | $433.3M | $268.6M | ||
| Q4 24 | $433.3M | $276.1M | ||
| Q3 24 | $454.1M | $255.2M | ||
| Q2 24 | $440.4M | $309.9M | ||
| Q1 24 | $446.8M | $317.7M |
负债/权益比MLABOUST
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $-15.4M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $-37.2M |
| 自由现金流率自由现金流/营收 | 27.7% | -59.8% |
| 资本支出强度资本支出/营收 | 1.1% | 35.0% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-64.8M |
8季度趋势，按日历期对齐
经营现金流MLABOUST
| Q4 25 | $18.8M | $-15.4M | ||
| Q3 25 | $8.2M | $-18.3M | ||
| Q2 25 | $1.9M | $-1.3M | ||
| Q1 25 | $12.7M | $-4.9M | ||
| Q4 24 | $18.1M | $-2.6M | ||
| Q3 24 | $5.3M | $-3.8M | ||
| Q2 24 | $10.7M | $-21.6M | ||
| Q1 24 | $12.9M | $-5.7M |
自由现金流MLABOUST
| Q4 25 | $18.0M | $-37.2M | ||
| Q3 25 | $7.1M | $-20.0M | ||
| Q2 25 | $884.0K | $-2.2M | ||
| Q1 25 | $11.9M | $-5.4M | ||
| Q4 24 | $17.3M | $-4.0M | ||
| Q3 24 | $3.5M | $-4.3M | ||
| Q2 24 | $9.9M | $-22.0M | ||
| Q1 24 | $12.3M | $-7.1M |
自由现金流率MLABOUST
| Q4 25 | 27.7% | -59.8% | ||
| Q3 25 | 11.7% | -50.7% | ||
| Q2 25 | 1.5% | -6.3% | ||
| Q1 25 | 19.2% | -16.6% | ||
| Q4 24 | 27.6% | -13.3% | ||
| Q3 24 | 6.0% | -15.4% | ||
| Q2 24 | 16.9% | -81.5% | ||
| Q1 24 | 21.0% | -27.4% |
资本支出强度MLABOUST
| Q4 25 | 1.1% | 35.0% | ||
| Q3 25 | 1.8% | 4.3% | ||
| Q2 25 | 1.7% | 2.5% | ||
| Q1 25 | 1.2% | 1.7% | ||
| Q4 24 | 1.3% | 4.8% | ||
| Q3 24 | 3.1% | 2.0% | ||
| Q2 24 | 1.5% | 1.3% | ||
| Q1 24 | 0.9% | 5.3% |
现金转化率MLABOUST
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
OUST
暂无分部数据
